Pharmasset, Inc. (Public, NASDAQ:VRUS)

[CubbieBlue]

Originally Posted by Michael Scally MD

What price did you buy the shares?

Even on a down day, VRUS is UP!!!

107.91

I'm pissed off because it still hasn't adjusted for the split, and I don't think it is going to. It's only play money, but still, that's fucking lame.

[Michael Scally MD]

Originally Posted by CubbieBlue

107.91

I'm pissed off because it still hasn't adjusted for the split, and I don't think it is going to. It's only play money, but still, that's fucking lame.

You will have to manually make the change.

[Michael Scally MD]

VRUS is UP 4+% in PM!!!

Pharmasset Announces 91% SVR12 From the PROTON Trial in Subjects With Hepatitis C Genotype 1
- Intent to-treat SVR12 of 91% (43 of 47) following a 24-week treatment regimen incorporating 12 weeks of PSI-7977 400 mg QD
Pharmasset Announces 91% SVR12 From the PROTON Trial in Subjects With Hepatitis C Genotype 1 (NASDAQ:VRUS)

PRINCETON, N.J., Sept. 6, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), announced today sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 400 mg dosed once daily in combination with peginterferon alfa 2a and ribavirin (Peg-IFN/RBV) in subjects with hepatitis C virus (HCV) genotype 1 who have not been treated previously. 43 out of 44 (98%) evaluable subjects achieved an SVR12, defined as HCV RNA below the limit of detection.

Ninety five treatment-naive patients with HCV genotype 1 were enrolled into two open-label arms of the PROTON trial, receiving either PSI-7977 200 mg QD (N=48) or 400 mg QD (N=47) for 12 weeks. Individuals in both arms received Peg-IFN/RBV for 24 weeks and were followed post-treatment to assess SVR12. Twenty-six subjects were enrolled in a placebo control arm and are receiving 48 weeks of Peg-IFN/RBV. Results from this study through the SVR12 endpoint are scheduled to be presented as part of a Presidential Plenary Session at the American Association for the Study of Liver Diseases (AASLD) meeting on Tuesday, November 8, 2011.

"I am very pleased with the results of this study which clearly demonstrate the benefit of the 400 mg dose of PSI-7977 with only 24 weeks of interferon for all subjects," stated Dr. Eric Lawitz, the study's principal investigator. "HCV therapy is becoming overly complex, and the elimination of 24 weeks of interferon and ribavirin as well as all response guided criteria for patients with HCV genotype 1 would be a welcomed simplification."

At the European Association for the Study of the Liver (EASL) in April 2011, Dr. David Nelson presented interim results from the PROTON trial showing that 43 out of 47 subjects receiving the 400 mg dose of PSI-7977 achieved an eRVR, defined as HCV RNA below the limit of detection.

[CubbieBlue]

Originally Posted by Michael Scally MD

You will have to manually make the change.

It did eventually adjust.

Total gain: $3k since I bought.

[Michael Scally MD]

Originally Posted by CubbieBlue

It did eventually adjust.

Total gain: $3k since I bought.

What %? That is the more important valuation. Also, compare to the S&P 500.

[CubbieBlue]

Originally Posted by Michael Scally MD

What %? That is the more important valuation. Also, compare to the S&P 500.

7.87% gain.

My comparison to the S&P is a little skewed now because I have a bunch of other stuff in my portfolio...some of it doing poorly as of this morning.

[Michael Scally MD]

Originally Posted by CubbieBlue

7.87% gain.

My comparison to the S&P is a little skewed now because I have a bunch of other stuff in my portfolio...some of it doing poorly as of this morning.

VRUS keeps going UP.

[CubbieBlue]

Originally Posted by Michael Scally MD

VRUS keeps going UP.

I know. Do you intend to pull the trigger anytime soon or ride it out long term?

[Michael Scally MD]

Prior to June 1, 2011, Pharmasset, Inc. submitted four abstracts to the American Association for the Study of Liver Diseases (“ AASLD ”) which summarize new data on PSI-7977 to be presented at their annual meeting in San Francisco which starts November 4, 2011 As previously disclosed, on August 2, 2011, the AASLD posted the titles of such abstracts on its website. On September 30, 2011, the AASLD released such abstracts to the public by posting them on its website. Pharmasset, Inc. - Current Report / http://files.shareholder.com/downloa...081/filing.pdf

The four abstracts are:

• Once Daily PSI-7977 plus RBV: Pegylated interferon-ALFA not required for Complete Rapid viral response in Treatment-naïve Patients with HCV GT2 or GT3


• Once-Daily PSI-7977 Plus Peg/RBV in Treatment-naïve Patients with HCV GT1: Robust End of Treatment Response Rates are Sustained Post-treatment


• Lack of Effect of the Nucleotide Analog Polymerase Inhibitor PSI-7977 on Methadone Pharmacokinetics and Pharmacodynamics


• PSI-7977 Has No Effect on QTcF Intervals at Therapeutic or Supratherapeutic Doses

[Michael Scally MD]

UP, UP, UP!!!

https://twitter.com/#!/adamfeuerstei...03650256207872